Scientists are advocating for the consideration of weight-loss medications, such as semaglutide (Ozempic and Wegovy), for children as young as six years old who are struggling with obesity. A recent study analyzed weight-loss trials involving 756 overweight children aged six to 17. Participants using older GLP-1 drugs lost an average of 11 pounds (5 kg), while those taking semaglutide lost an average of nearly 2.5 stones (18 kg).
According to Dr. Manpreet Kaur Oberoi, one of the academics involved in the study, the medicines were found to be "significantly efficient in lowering the BMI, weight, heart rate and systolic blood pressure and in improving quality of life, while maintaining a manageable safety profile." The findings suggest that these medications could be beneficial for children facing the physical and mental health challenges associated with obesity, provided the benefits outweigh the risks.
In England alone, approximately 1.2 million children are classified as significantly obese. Childhood obesity can lead to long-term health issues, including heart disease, stroke, Type 2 diabetes, cancer, and joint problems, as well as significantly impacting self-esteem and social interactions. The study's findings are being presented as a potential strategy to combat this growing crisis, especially considering that 80% of obese adolescents go on to become obese adults.
The article acknowledges the discomfort many may feel regarding the idea of medicating young children for weight loss. However, it argues that the current reality of childhood obesity, exacerbated by an environment saturated with highly processed, calorie-dense foods and reduced opportunities for physical activity, necessitates exploring all potential solutions. The author suggests that traditional educational approaches alone have proven insufficient against the pervasive influence of ultra-processed foods.
While parental responsibility in guiding children's diets is emphasized, the piece also expresses sympathy for parents in 2026, citing increased safety concerns that limit children's outdoor activities and the proliferation of tempting, inexpensive treats. The debate over the use of weight-loss injections in children highlights the complex interplay of scientific advancement, public health challenges, and societal attitudes towards childhood obesity and its treatment.